{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"16.7","value":"3.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Overall Response Rate (ORR) of treatment with milademetan, as defined as the percentage of patients who have achieved confirmed complete response (CR) or Partial Response (PR) according to RECIST v1.1","dispersionType":"95% Confidence Interval","groups":[{"description":"260 mg once daily (QD) orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle","id":"OG000","title":"Milademetan (RAIN-32)"}],"paramType":"NUMBER","populationDescription":"This analysis is conducted in all participants within the Centrally confirmed population (CCP) which is defined as all participants who had at least one dose of study treatment and also have WT TP53 and MDM2 amplification with CN ≥ 8 by central testing.","reportingStatus":"POSTED","timeFrame":"From first dose date to first confirmed complete or partial response or study completion date; up to 23.5 months.","title":"To Determine the ORR of Treatment With Milademetan in Patients With Advanced/Metastatic Solid Tumors With MDM2 Gene Amplification.","type":"PRIMARY","unitOfMeasure":"percentage of participants"}